Over the last decade, there has been a revolutionary transformation in the clinical treatment of individuals with advanced melanoma, brought about by the adoption of immunotherapies targeting PD1 and/or CTLA-4, along with targeted therapies inhibiting BRAF/MEK [3]. The gene discussed is BRAF; the disease is melanoma.